Clinical trial · Observational
Ocular Blood Flow in Colorectal Cancer Patients
Exploratory Study Investigating Ocular Blood Flow in Colorectal Cancer Patients Before and After Treatment With Anti-angiogenic Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow recruitment
Summary
Brief summary (as posted)
In colorectal cancer therapy anti-angiogenic strategies have become a cornerstone of treatment regimens in the metastatic setting. Addition of bevacizumab to conventional chemotherapeutic combination regimens has improved the median overall survival of advanced colorectal cancer patients by approximately 5 months. Selecting patients, who will benefit from anti-angiogenic approaches, would be highly desirable in order to optimize treatment strategies. Changes in ocular blood flow may be an attractive biomarker for predicting treatment response. In light of the given alternative first line treatment options such a predictive biomarker would be of clinical benefit. In the proposed study the investigators will assess potential changes in the ocular blood flow of mCRC patients after treatment with standard of care anti-angiogenic/cytotoxic therapy as an early predictive marker of treatment response as assessed by standard CT-scan
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Correlation between ocular blood flow (retinal blood flow) and treatment response
- timeFrame
- Within 2-3 months at restaging
- description
- mean RBCs velocity in Hz and blood flow in arbitrary units will be reported and correlated with response rates (CR,PR,SD or PD)
- measure
- Correlation between retinal vessel diameter and treatment response
- timeFrame
- Within 2-3 months at restaging
- description
- Retinal vessel diameter will be reported and correlated with response rates (CR,PR,SD or PD)
- measure
- Changes in retinal surface before and after therapy as measured by optical coherence tomography
- timeFrame
- Within 2-3 months at restaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female patients (age 18 and over) suffering from mCRC. * Normal findings in ophthalmic examination (except the investigator finds an abnormality irrelevant for the purpose of the study.) * Patients, which are scheduled for standard of care treatment with chemotherapy plus bevacizumab Exclusion Criteria: * Refusal to give informed consent * Severe hypertension (RR ≥180/110) * Epilepsy * Pregnancy and breastfeeding women
References
Publications (0)
Data not yet available